Evogene Schedules Second Quarter 2025 Financial Results Release
Evogene (NASDAQ: EVGN), a computational biology company focused on life-science product discovery and development, has scheduled its Q2 2025 financial results release for Tuesday, August 19, 2025. The company will host a conference call to discuss the results at 9:00 AM ET (4:00 PM Israel time).
Interested participants must register in advance through the company's dedicated conference link. A recording of the conference will be made available on Evogene's website following the event.
Evogene (NASDAQ: EVGN), un'azienda di biologia computazionale specializzata nella scoperta e nello sviluppo di prodotti per le scienze della vita, ha programmato la pubblicazione dei risultati finanziari del secondo trimestre 2025 per martedì 19 agosto 2025. La società terrà una conference call per discutere i risultati alle 9:00 AM ET (16:00 ora di Israele).
I partecipanti interessati devono registrarsi in anticipo tramite il link dedicato fornito dall'azienda. Una registrazione della conferenza sarà disponibile sul sito web di Evogene dopo l'evento.
Evogene (NASDAQ: EVGN), una empresa de biología computacional enfocada en el descubrimiento y desarrollo de productos para ciencias de la vida, ha programado la publicación de sus resultados financieros del segundo trimestre de 2025 para el martes 19 de agosto de 2025. La compañía realizará una llamada conferencia para discutir los resultados a las 9:00 AM ET (4:00 PM hora de Israel).
Los interesados deben registrarse con anticipación a través del enlace dedicado de la empresa. Una grabación de la conferencia estará disponible en el sitio web de Evogene después del evento.
Evogene (NASDAQ: EVGN)는 생명과학 제품 발굴 및 개발에 중점을 둔 컴퓨터 생물학 회사로, 2025년 8월 19일 화요일에 2025년 2분기 재무 결과 발표를 예정하고 있습니다. 회사는 동부 표준시 오전 9시(이스라엘 시간 오후 4시)에 결과를 논의하기 위한 컨퍼런스 콜을 개최할 예정입니다.
참석을 원하시는 분들은 회사의 전용 컨퍼런스 링크를 통해 사전 등록해야 합니다. 컨퍼런스 녹음본은 행사 후 Evogene 웹사이트에서 제공될 예정입니다.
Evogene (NASDAQ : EVGN), une entreprise de biologie computationnelle spécialisée dans la découverte et le développement de produits en sciences de la vie, a programmé la publication de ses résultats financiers du deuxième trimestre 2025 pour le mardi 19 août 2025. La société tiendra une conférence téléphonique pour discuter des résultats à 9h00 ET (16h00 heure d’Israël).
Les participants intéressés doivent s’inscrire à l’avance via le lien dédié fourni par l’entreprise. Un enregistrement de la conférence sera disponible sur le site web d’Evogene après l’événement.
Evogene (NASDAQ: EVGN), ein Unternehmen für computergestützte Biologie mit Schwerpunkt auf der Entdeckung und Entwicklung von Produkten im Bereich der Lebenswissenschaften, hat die Veröffentlichung der Finanzergebnisse für das 2. Quartal 2025 am Dienstag, den 19. August 2025 angekündigt. Das Unternehmen wird eine Telefonkonferenz zur Besprechung der Ergebnisse um 9:00 Uhr ET (16:00 Uhr Israel-Zeit) abhalten.
Interessierte Teilnehmer müssen sich im Voraus über den speziellen Konferenzlink des Unternehmens registrieren. Eine Aufzeichnung der Telefonkonferenz wird nach der Veranstaltung auf der Evogene-Website verfügbar sein.
- None.
- None.
Zoom conference call scheduled for August 19, 2025, 9:00 AM ET
REHOVOT,
Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time).
To attend the conference, please register in advance:
https://www.veidan-conferencing.com/evogene
The entire conference will be available online on the company's website a few days after.
About Evogene:
Evogene Ltd. (Nasdaq, TASE: EVGN) is a computational biology company leveraging big data and artificial intelligence, aiming to revolutionize the development of life-science-based products by utilizing cutting-edge technologies to increase the probability of success while reducing development time and cost.
Evogene established three unique tech-engines - MicroBoost AI, ChemPass AI and GeneRator AI. Each tech-engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI).
Evogene uses its tech-engines to develop products through strategic partnerships and collaborations, and its subsidiaries, including:
- Biomica Ltd. (www.biomicamed.com) - developing and advancing novel microbiome-based therapeutics to treat human disorders powered by MicroBoost AI;
- Lavie Bio Ltd. (www.lavie-bio.com) - developing and commercially advancing, microbiome-based ag-biologicals powered by MicroBoost AI;
- AgPlenus Ltd. (www.agplenus.com) - developing next-generation ag chemicals for effective and sustainable crop protection powered by ChemPass AI;
- Casterra Ag Ltd. (www.casterra.co) - developing and marketing superior castor seed varieties producing high yield and high-grade oil content on an industrial scale for the biofuel and other industries powered by GeneRator AI.
For more information, please visit: www.evogene.com.
Contact:
ir@evogene.com
Tel: +972-8-9311901
Logo: https://mma.prnewswire.com/media/1947468/4576969/Evogene_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/evogene-schedules-second-quarter-2025-financial-results-release-302515858.html
SOURCE Evogene
FAQ
When will Evogene (EVGN) release its Q2 2025 financial results?
What time is Evogene's Q2 2025 earnings conference call?
How can investors join Evogene's Q2 2025 earnings call?
Where can I find a replay of Evogene's Q2 2025 earnings call?
